Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks
CTR20262411Phase 2Active
- Sponsor
- Chengdu Institute of Biological Products
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of conestat alfa in hereditary angioedema (HAE), sponsored by Chengdu Institute of Biological Products. Started Jul 2026; status: active.
02
Drugs
conestat alfa
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on CTR20262411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262411.